News | February 17, 2008

Drug-Coated Balloons Reduce Late Loss During Angioplasty of the Leg

February 18, 2008 - Treating patients who have occlusive femoropopliteal disease with paclitaxel-coated balloons during angioplasty — rather than the uncoated variety — leads to significant reductions in late lumen loss and target-lesion revascularization (TLR), according to a study published in the February 14, 2008, issue of The New England Journal of Medicine.

Data from the THUNDER (Local Taxane with short time contact for reduction of restenosis in distal arteries) trial, led by Gunnar Tepe, MD, of Eberhard Karls University (Tübingen, Germany), was presented in Washington, D.C., at the TCT 2007 symposium.
The trial, randomized 154 patients with stenosis of a femoropopliteal artery to treatment with angioplasty using paclitaxel-coated balloons, angioplasty with uncoated balloons but with paclitaxel dissolved in the contrast medium, or normal angioplasty without any additional paclitaxel (control). The results showed that at a 6-month follow-up, the paclitaxel-coated balloon group had significantly improved late loss and TLR, compared with controls.

The lack of effect in the patients treated with paclitaxel in the contrast medium differed from previous findings in animal models. Dissolving paclitaxel in contrast medium is known to enhance drug solubility, but the authors explained that most studies examining this method were performed in the coronary circulation, which differs with respect to vessel diameter and capillary supply of the muscle from the peripheral circulation in the leg. The authors noted that this could explain why paclitaxel in the contrast medium failed to work in the THUNDER trial, because “these differences influence local drug effects,” they wrote.

Even though TLR was significantly reduced in the coated-balloon group, repeat revascularizations appeared to be angiographically — not clinically — driven since symptom measurements remained the same at six months.

The trial however does not offer a comparison to bare metal stents (BMS) for peripheral revascularization, despite increasing research now showing that BMS are better than angioplasty alone in treating lesions of the superficial femoral artery (SFA).

For more information:

Related Content

Gore Molding & Occlusion Balloon for Endovascular Aortic Repair Receives FDA Approval
Technology | Balloon Catheter | August 23, 2018
W. L. Gore & Associates Inc. (Gore) announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the Gore...
Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon
Technology | Balloon Catheter | March 21, 2018
Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k...
Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...
Videos | Balloon Catheter | October 30, 2015
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford Uni
Overlay Init